Invitrogen Wins One Patent Battle Against Clontech on Appeal; Remaining Two Patents in District Court | GenomeWeb

NEW YORK (GenomeWeb News) - Clontech's PowerScript products infringe a single patent held by Invitrogen, an appeals court has ruled, while two related patents in the case are being reviewed by the original district court, according to Invitrogen.

 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.